Current Diabetes Reports

Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
Metapress, Gale, and Springer

  1. Pathogenesis of pain in peripheral diabetic neuropathy.

    Current Diabetes Reports 7(6):429 (2007) PMID 18255005

    Recent advances in understanding the pain associated with diabetic neuropathy are likely to provide significant mechanistic insights and offer better therapies. In clinical research, new tools for measuring neuropathic pain and validation of histologic and other biomarkers will provide the found...
  2. Contrast-induced nephropathy: update with special emphasis on patients with diabetes.

    Current Diabetes Reports 7(6):454 (2007) PMID 18255010

    Contrast-induced nephropathy (CIN) continues to be a significant complication of the increasing use of iodinated contrast media. There have been few new insights into pathogenesis; despite multiple strategies aimed at prophylaxis, very few have proven efficacious. This article reviews our curren...
  3. Microangiopathy in older patients with diabetes mellitus.

    Current Diabetes Reports 7(6):437 (2007) PMID 18255006

  4. Topical treatment for painful diabetic neuropathy?

    Current Diabetes Reports 7(6):407 (2007) PMID 18255000

  5. Temperature monitoring to assess, predict, and prevent diabetic foot complications.

    Current Diabetes Reports 7(6):416 (2007) PMID 18255002

    Preventing foot complications in high-risk patients with diabetes is often overlooked. Assessing risk factors and providing standard preventative care is low tech and relatively inexpensive. The objective of this article is to discuss standard screening and prevention practices and using tempera...
  6. Statin therapy in renal disease: harmful or protective?

    Current Diabetes Reports 7(6):467 (2007) PMID 18255012

    Chronic kidney disease (CKD) creates one of the highest-risk atherosclerotic states that can occur in human beings. The use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) has gained widespread acceptance in the general population for the purposes of lowering low-density ...
  7. Targeting skeletal muscle AMP-activated protein kinase to treat type 2 diabetes.

    Current Diabetes Reports 7(6):399 (2007) PMID 18254999

  8. The step-by-step program for reducing diabetic foot problems: a model for the developing world.

    Current Diabetes Reports 7(6):425 (2007) PMID 18255004

    The prevalence of diabetes is increasing globally, particularly in the developing world. The diabetic foot is one of the most devastating chronic complications of diabetes. The Step-by-Step project was initiated in India, with participation from neighboring countries and Tanzania, to improve dia...
  9. Neuropathy associated with prediabetes: what is new in 2007?

    Current Diabetes Reports 7(6):420 (2007) PMID 18255003

    Length-dependent polyneuropathy has long been recognized as a frequent complication of diabetes. A decade of observational and epidemiologic studies support the concept that intermittent hyperglycemia or insulin resistance associated with prediabetes may be sufficient to damage distal nerves. Fe...
  10. Examining diabetic nephropathy through the lens of mouse genetics.

    Current Diabetes Reports 7(6):459 (2007) PMID 18255011

    Although diabetic nephropathy occurs in only a minority of patients with diabetes, it is the major cause of end-stage renal disease in the United States. Hyperglycemia and hypertension are important factors predisposing patients to diabetic nephropathy, but accumulating evidence points to critic...
  11. Microalbuminuria as a target to improve cardiovascular and renal outcomes in diabetic patients.

    Current Diabetes Reports 7(6):439 (2007) PMID 18255007

    Microalbuminuria has been shown to be a risk factor for adverse renal and cardiovascular outcomes in patients with diabetes mellitus. This risk appears to increase with higher levels of albuminuria. There is also evidence that reducing the level of albuminuria improves these outcomes. This revie...
  12. Management of painful diabetic neuropathy: what is new or in the pipeline for 2007?

    Current Diabetes Reports 7(6):409 (2007) PMID 18255001

    Approximately one of three diabetic patients is affected by distal symmetric polyneuropathy, which represents a major health problem because it may present with partly excruciating neuropathic pain and is responsible for substantial morbidity and increased mortality. Treatment is based on three ...
  13. The use of motivational interviewing in weight loss.

    Current Diabetes Reports 7(5):386 (2007) PMID 18173973

    Within the past two decades, motivational interviewing has emerged as a useful strategy to help individuals develop motivation to change health behavior and sustain those efforts. This article reviews the preliminary but burgeoning literature that supports the effectiveness of motivational inter...
  14. Improving diabetes care and education of Latinos: a challenging but important mission.

    Current Diabetes Reports 7(5):321 (2007) PMID 18173963

  15. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.

    Current Diabetes Reports 7(5):340 (2007) PMID 18173966

    Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes. It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors. In type 2 diabetes, the two strategies reduce hemoglobin A(1c) by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%. They are ...
  16. Cultural approaches to diabetes self-management programs for the Latino community.

    Current Diabetes Reports 7(5):391 (2007) PMID 18173974

    The issue of diabetes within the Latino population of the United States is of such magnitude that reviewing previously published studies on culturally oriented diabetes self-management interventions is imperative to further understanding and progress on this matter. The purpose of this revision ...
  17. Who should benefit from the use of alpha-glucosidase inhibitors?

    Current Diabetes Reports 7(5):333 (2007) PMID 18173965

    Although most commonly used drugs such as biguanides, sulfonylureas, and more recently, thiazolidinediones, are effective in controlling fasting hyperglycemia, a high percentage of patients have sustained elevated hemoglobin A(1c) because of persistent elevation of postprandial plasma glucose (P...
  18. Diabetes self-management education and third-party reimbursement: what are the options?

    Current Diabetes Reports 7(5):381 (2007) PMID 18173972

    Attaining reimbursement for diabetes self-management training can be daunting. To some it may be enough to frighten them off. But for the strong of heart you should consider the options that are available to you. Billing for services directly to the patient as a fee for service is one option. Ot...
  19. How should the clinician most effectively prevent type 2 diabetes in the obese person at high risk?

    Current Diabetes Reports 7(5):353 (2007) PMID 18173968

    The dramatic increase in newly diagnosed cases of type 2 diabetes (T2D) has developed into a major public health concern worldwide. Conversely, several clinical studies have demonstrated that preventive efforts can significantly reduce the risk of developing diabetes. There is a clear consensus ...
  20. Which basal insulin should be used in patients with type 2 diabetes mellitus?

    Current Diabetes Reports 7(5):348 (2007) PMID 18173967

    The initiation of insulin therapy is a significant event for patients with diabetes and the physicians who care for them. Reluctance to begin insulin is multifactorial, with major stumbling blocks being the perceived complexity of insulin and fear of hypoglycemia. Recent guidelines supporting ea...